Valuation: Orthocell Limited

Market Cap 200M 138M 122M 112M 105M 196M 13.01B 1.35B 522M 6.42B 518M 507M 22.33B P/E 2026 *
-18.4x
P/E 2027 * -36.8x
Enterprise Value 157M 109M 95.57M 88.15M 82.44M 154M 10.23B 1.06B 410M 5.05B 408M 399M 17.56B EV / Sales 2026 *
12.5x
EV / Sales 2027 * 7.28x
Free-Float
83.36%
Yield 2026 *
-
Yield 2027 * -
1 day-2.04%
1 week-6.49%
Current month-5.88%
1 month-10.00%
3 months-4.00%
6 months-32.71%
Current year-33.64%
1 week 0.71
Extreme 0.71
0.79
1 month 0.71
Extreme 0.71
0.82
Current year 0.7
Extreme 0.7
1.16
1 year 0.7
Extreme 0.7
1.6
3 years 0.32
Extreme 0.32
1.79
5 years 0.3
Extreme 0.3
1.79
10 years 0.1
Extreme 0.105
1.79
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2006-03-20
Chief Executive Officer 60 2006-03-20
Director of Finance/CFO - 2025-07-31
Director TitleAgeSince
Director/Board Member 60 2006-03-20
Director/Board Member 60 2023-03-07
Chairman - 2023-05-31
Date Insider Type Main position Quantity % Market Cap.
05-02Buy 23,615 0.0087%
04-30Buy

Chairman

25,000 0.0092%
02-24Buy 26,041 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
-2.04%-6.49%-34.25%+110.22% 138M
+3.74%+6.61%+21.72%-6.11% 183B
+0.69%-0.09%-23.18%+22.79% 142B
+3.87%+6.25%-4.36%-20.70% 134B
-0.04%-1.09%-57.30%-17.62% 66.08B
+1.42%+3.44%+18.21%-0.75% 51.63B
+0.26%-0.90%-27.36%-32.49% 43.38B
+3.68%+5.87%+11.89%+10.22% 37.18B
+2.76%+3.41%+6.45%+42.08% 36.25B
+0.79%+6.10%-9.86%-18.72% 29.51B
Average +1.60%-0.69%-9.80%+8.89% 72.31B
Weighted average by Cap. +2.36%-0.60%-4.93%-2.61%

Financials

2026 *2027 *
Net sales 12.55M 8.66M 7.62M 7.03M 6.58M 12.32M 816M 84.49M 32.73M 403M 32.5M 31.8M 1.4B 23.55M 16.25M 14.3M 13.19M 12.34M 23.12M 1.53B 159M 61.41M 755M 61M 59.67M 2.63B
Net income -12.5M -8.62M -7.59M -7M -6.55M -12.27M -813M -84.15M -32.6M -401M -32.38M -31.67M -1.39B -7.85M -5.42M -4.77M -4.4M -4.11M -7.71M -510M -52.85M -20.47M -252M -20.33M -19.89M -876M
Net Debt -42.75M -29.49M -25.96M -23.95M -22.4M -41.97M -2.78B -288M -111M -1.37B -111M -108M -4.77B -28.75M -19.83M -17.46M -16.11M -15.06M -28.22M -1.87B -194M -74.97M -922M -74.46M -72.85M -3.21B
Logo Orthocell Limited
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Employees
-
Date Price Change Volume
26-06-25 A$0.7200 -2.04% 531,974
26-06-24 A$0.7350 -1.34% 285,218
26-06-23 A$0.7450 -2.61% 344,329
26-06-22 A$0.7650 +4.08% 698,405
26-06-19 A$0.7350 -4.55% 482,123
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7350AUD
Average target price
1.250AUD
Spread / Average Target
+70.07%

Quarterly revenue - Rate of surprise